Lanreotide is a synthetic 8-amino-acid cyclic somatostatin analog (MW ~1096.3 g/mol) available as a long-acting deep subcutaneous depot injection (Somatuline Depot/Autogel). It is FDA-approved for acromegaly and for the treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Lanreotide self-assembles into nanotubes at high concentration, enabling sustained drug release over 4 weeks from a single injection.
Category: Endocrine / Somatostatin Analog. Evidence rating: A (strong human clinical data).
Clinical status: FDA-approved (Somatuline Depot for acromegaly 2007; GEP-NETs 2014)
Lanreotide binds with high affinity to somatostatin receptor subtypes SSTR2 and SSTR5, and with moderate affinity to SSTR3. Like octreotide, it inhibits GH, TSH, and gastrointestinal and pancreatic endocrine secretions. Its antiproliferative mechanism involves SSTR2-mediated cell cycle arrest,…
Research base: 0 registered clinical trials and 1 indexed publication reference Lanreotide.
Safety considerations: Common (>10%): diarrhea (26-37%), abdominal pain (14-19%), cholelithiasis (14-20%); Injection site reactions: pain, mass, induration, erythema at injection site (9-22%); Glucose metabolism alterations: hyperglycemia (7-14%) or hypoglycemia (7%).
Reviewed by the PeptideAtlas Editorial Team.
| Amino-acid sequence | D-2Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 (disulfide bridge Cys2-Cys7) |
|---|---|
| Molecular weight | ~1096.3 g/mol |
| CAS number | 108736-35-2 |
| Half-life | ~23-30 days (effective duration from Autogel depot); terminal half-life ~23-30 hours |
| Bioavailability | ~73-90% from deep subcutaneous depot |
| Production method | synthetic |
| Anti-doping status | not-listed |
| US regulatory status | FDA-approved. Somatuline Depot approved 2007 for acromegaly; 2014 for GEP-NETs (based on CLARINET trial). |
Related peptides: Octreotide, Pasireotide, Somatostatin.
Both are somatostatin analogs with similar receptor binding profiles (preferential SSTR2 and SSTR5 affinity). Key differences: lanreotide Autogel is a pre-filled deep subcutaneous injection enabling self-administration, while octreotide LAR requires IM injection by a healthcare professional. The CLARINET trial provided Level 1 evidence for lanreotide in GEP-NETs; PROMID did so for octreotide in…
Yes. Somatuline Autogel is the only somatostatin analog depot formulation designed for deep subcutaneous self-injection. Patients or caregivers can be trained to administer it in the upper outer quadrant of the buttock.
CLARINET (Controlled study of Lanreotide Antiproliferative Response in Neuroendocrine Tumors) was a randomized, double-blind, placebo-controlled Phase III trial (n=204) that demonstrated lanreotide significantly prolonged progression-free survival in nonfunctioning GEP-NETs (HR 0.47, p<0.001). This led to FDA approval for GEP-NETs in 2014.
Coverage on this site: Representative Peptides for In Vivo Tumor Imaging, Macrocyclic Peptide Drugs: Structures, Pipelines and Oral Prospects.